SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
ArriVent BioPharma, Inc. Common Stock (AVBP) has a negative trailing P/E of -6.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 32.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -16.52%, forward earnings yield 3.05%. PEG 0.10 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (91/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.10); analyst target implies upside (+59.2%).
- Forward P/E 32.8 — analysts expect a return to profitability with estimated EPS of $0.84 for FY2029.
- PEG Ratio 0.10 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -16.52% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 3.05% as earnings recover.
- Analyst consensus target $44.00 (+59.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
91/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AVBP
Valuation Multiples
P/E (TTM)-6.1
Forward P/E32.8
PEG Ratio0.10
Forward PEG0.10
P/B Ratio3.28
P/S Ratio0.00
EV/EBITDA-6.5
Per Share Data
EPS (TTM)$-4.32
Forward EPS (Est.)$0.84
Book Value / Share$7.99
Revenue / Share$0.00
FCF / Share$-4.18
Yields & Fair Value
Earnings Yield-16.52%
Forward Earnings Yield3.05%
Dividend Yield0.00%
Analyst Target$44.00 (+59.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2021 |
-0.5 |
0.00 |
0.62 |
0.00 |
- |
| 2022 |
-18.2 |
0.19 |
3.84 |
0.00 |
- |
| 2023 |
-9.2 |
-0.09 |
4.22 |
0.00 |
- |
| 2024 |
-10.4 |
-0.58 |
3.25 |
0.00 |
- |
| 2025 |
-4.7 |
-0.07 |
2.52 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2021 |
$-1.54 |
$0.00 |
$-51.61M |
- |
| 2022 |
$-1.10 |
$0.00 |
$-36.91M |
- |
| 2023 |
$-2.17 |
$0.00 |
$-69.33M |
- |
| 2024 |
$-2.56 |
$0.00 |
$-80.49M |
- |
| 2025 |
$-4.32 |
$0.00 |
$-166.31M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-3.76 |
$-4.12 – $-3.19 |
$125K |
$76.48K – $177.65K |
9 |
| 2027 |
$-3.25 |
$-3.34 – $-3.15 |
$35.94M |
$31.35M – $40.53M |
6 |
| 2028 |
$-1.47 |
$-3.61 – $1.90 |
$130.96M |
$130.96M – $130.96M |
7 |
| 2029 |
$0.84 |
$0.42 – $1.31 |
$266.77M |
$163.22M – $379.14M |
2 |
| 2030 |
$3.55 |
$1.76 – $5.49 |
$433.92M |
$265.48M – $616.69M |
5 |
